

6 February 2025

ASX Announcement

Notice of Listed Options and exercise instructions

MELBOURNE Australia, 6 February 2025: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) notes that the Company currently has 27,319,837 listed options on issue (ASX:ILAO) (**Listed Options**) expiring on 14 March 2025 with an exercise price of \$0.06 per option.

Important information regarding Listed Options

ASX Code:	ILAO
Exercise price:	\$0.06 per option
Expiry date:	14 March 2025
Option terms:	Refer to Prospectus dated 26 February 2024

The Company wishes to inform the holders of the Listed Options that they can exercise all or part of their Listed Options prior to the Expiry Date by providing the Company:

1. A completed exercise notice specifying the number of Listed Options being exercised; and
2. Payment of funds for the total exercise price for the number of Listed Options being exercised.

Holders can log into their accounts on the [Automic Investor Portal](#) to access their option-exercise forms.

Once logged in, click on “Documents and Statements.” Select “Other Documents,” then download the ILAO Option Exercise Form. Holders can exercise their options by using BPAY or EFT.

If you are a Holder and have any questions regarding the expiry of the Listed Options or their exercise, please contact the Company's share registry, Automic Registry on:

Phone: 1300 288 664; or
Email: hello@automic.com.au

- Ends -

To subscribe to Island's monthly newsletter, [IslandWatch](#), and other forms of email communications, please visit [this page](#) of our website.



Approved for release to the ASX by:
*David Foster, CEO & Managing Director
Island Pharmaceuticals Limited*

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.